Jasper’s Expanding Pipeline

Jasper maintains worldwide rights to develop and commercialize JSP191 and eHSCs in all indications.

 

Product
RESEARCH
PRECLINICAL
CLINICAL
R&D PARTNER
JSP191 Conditioning
AML/MDS
SCID
Autoimmune (Lupus, Scleroderma, MS)
Fanconi’s Anemia
Partner
Sickle Cell Disease
Partner
Chronic Granulomatous Disease
Partner
GATA2 MDS
Partner
Gene Therapy – Sickle Cell
Partner
Gene Therapy – X-SCID
Partner
Jasper eHSC Platform
Thalassemias
Sickle Cell Disease
Autoimmune Diseases
Top